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Following recent catastrophic events, such as September
11th and Hurricane Katrina, and in response to threats of
future national disasters, government, public and private
organizations have worked to devise response plans to
be implemented in the event of an emergency.
As of May 25, 2006, the Department of Homeland
Security established an all-hazards approach to improve
the ability of the United States to handle domestic
incidents. The plan incorporates many disciplines into
a unified structure and includes homeland security,
emergency management, law enforcement, firefighting,
public works, public health, responder and recovery
worker health and safety, emergency medical services,
and the private sector. Further, it establishes protocols
to help protect the country from terrorist attacks and
other national disasters in order to protect public health,
safety, property, and the environment, save lives, and
reduce post-traumatic consequences of such events.
In addition, over the past three years, Health Systems
Research, Inc., in collaboration with the Health
Resources and Services Administration and the Centers
for Disease Control and Prevention, has assisted the
Agency of Healthcare Research and Quality to share
information and tools to help public health officials,
health system decision makers, and providers detect
and respond to acts of bioterrorism. It has designed and
conducted a series of Web conferences on bioterrorism
and health systems preparedness.
Finally,theNationalBioterrorismHospitalPreparedness
program has worked to improve state, local, and
hospital preparedness and response to bioterrorism and
other public health emergencies. The mission of the
program is to prepare hospitals and health care systems
to deliver coordinated and effective care to disaster
victims.
For more information about these initiatives and
trainings visit www.hsrnet.com, www.dhs.gov, and
www.hrsa.gov
A recent report on the Food and Drug Administration's
(FDA) review of direct-to-consumer (DTC)
advertisements by pharmaceutical companies has
prompted a discussion about whether increased funding
is needed to allow the FDA to better regulate the
industry's marketing efforts. The report, Prescription
Drugs: Improvements Needed in FDA ' Oversight of
Direct-to-Consumer Advertising, Prescription Drugs:
Improvements Needed in FDA's Oversight ofDirect-to-
Consumer Advertising was released by the Government
Accountability Office (GAO) in December 2006.
Among the findings was GAO's conclusion that
the FDA reviews only a "small portion" of the DTC
materials it receives. The GAO also raised questions
about the effectiveness of the regulatory letters the
FDA sends to companies when DTC advertisements
are "violative."
SenatorHerb Kohl (D-WI)metwithFDACommissioner
Dr. Andrew von Eschenbach on January 10, 2007 to
discuss the regulation of DTC ads. Senator Kohl is
the Chairman of the Agriculture Subcommittee of the
Senate Appropriations Committee panel, which has
jurisdiction over the FDAbudget. Senator Kohl also sent
a letter to President Bush seeking additional funding in
the Fiscal Year 2008 budget request to allow the FDA
"to effectively review and regulate" DTC advertising
of prescription drugs. Senator Kohl expressed concern
that "staff and funding levels [at the FDA] have not kept
up with the increase in advertisements." According to
the GAO, drug company spending on DTC advertising
increased dramatically between 1997 and 2005, but the
budget for the FDA's DTC review group has increased
only slightly since its inception in 2002.
Currently, the FDA has oversight of DTC ads, but
there is no requirement that companies have their
ads approved or screened prior to airing. If the FDA
identifies a violation of laws or regulations in DTC
advertising material, the agency may issue a regulatory
letter asking the drug company to take specific
actions. However, the GAO report also questioned
the effectiveness of the regulatory letters issued by the
agency. According to the report, the FDA has issued
fewer letters per year since 2002, when legal review of
all draft regulatory letters was first required. The report
also concludes that the agency has had only "limited"
success in halting the dissemination of violative DTC
materials. The 19 regulatory letters issued by the FDA
in 2004 and 2005 were, on-average, issued 8 months
after the materials were first disseminated. The report
notes that "by the time the FDA issued these letters,
companies had already discontinued use of more than
half of the violative materials." Further, the GAO
says that receipt of regulatory letters from the FDA
did not always prevent drug companies from later
disseminating similar violative materials for the same
drugs.
The GAO report recommends that the FDA document
the criteria it will use for prioritizing DTC materials
for review by systematically applying that criteria to
the materials it receives and tracking which materials it
reviews. However, the report also states that the U.S.
Department of Health and Human Services "disagreed
with the recommendations, stating that they would
require vastly increased staff."
Meanwhile, the pharmaceutical industry is making an
effort to increase self-regulation of DTC ads. In 2005,
the Pharmaceutical Research & Manufacturers of
America (PhRMA) released 15 "Guiding Principles"
on DTC advertising that were intended to help
companies in the industry self-regulate their marketing
efforts. The Guiding Principles addressed issues such
as compelling pharmaceutical companies to submit
their ads to the FDA for review prior to being aired,
including information about other options for treatment
(such as diet and lifestyle), and holding conversations
with physicians prior to the launch of a new DTC
campaign.
Research involving human embryonic stem cells has
stirred much debate in the United States in the past
several years. Opponents of such research liken the
harvesting of stem cells to abortion because embryos
are destroyed in the process, and argue that it is wrong
to destroy human life. Supporters, however, emphasize
the important medical breakthroughs that such
research may afford, such as a cure for Alzheimer's
and Parkinson's disease.
In 2001, President Bush announced that tederal tunding
could be awarded for stem cell research, but only
under certain conditions. First, researchers must have
harvested the cells prior to August 9, 2001. Second,
researchers could only harvest cells from embryos that
were created, but not ultimately used, for reproductive
purposes. Finally, embryo donors must provide their
consent, and may not receive any financial inducements
for their donation.
In 2005, Congress tried to expand the scope of President
Bush's federal policy, with the passage of H.R. 810, the
Stem Cell Research Enhancement Act (the Act). The
bill would have allowed for research on embryonic
stem cells regardless of the date researchers harvested
them. In 2006, President Bush vetoed the bill.
With the Democrats in control of Congress, and Senator
Edward Kennedy's (D-MA) appointment as Chairman
of the U.S. Senate Committee on Health, Education,
Labor, and Pensions, the House reintroduced the Act as
H.R. 3. Although the House passed the bill, it did not
achieve the necessary two-thirds margin to overturn
the President's likely veto. The Senate has placed the
bill on its calendar for discussion.
Recent polls and scientific studies may shape the
future of stem cell legislation. Polls indicate that most
Americans support stem cell research. Furthermore, a
scientific study published in January 2007 indicated that
researchers may not need to destroy embryos in order to
obtain viable stem cells; rather, amniotic fluid may also
yield stem cells suitable for research. Opponents of the
Act may use this study to argue that the harvesting of
embryonic cells is now entirely unnecessary in order
to conduct stem cell research. Supporters of the bill,
however, note that cells harvested from amniotic fluid
may not provide the same research potential as cells
harvested from embryos.
On December 13, 2006, Dr. Andrew von Eschenbach
was sworn in as Commissioner of the Food and
Drug Administration (FDA) following the Senate's
confirmation by a vote of 80 to 11 six days earlier.
Although Dr. von Eschenbach's nomination occurred
in March 2006, his confirmation had been on hold
since September. Members of both parties protested
the confirmation, largely because of political
controversy surrounding the FDA approval of Plan B,
the emergency contraception pill, for sale to adults
without a prescription. As Acting Commissioner, Dr.
von Eschenbach's approval of over-the-counter Plan
B sales in August quieted many Democrats' objections
to his confirmation. A vocal minority of Republicans
continuedto protest Dr. von Eschenbach's confirmation
over concerns surrounding drug importation and the
investigation of Ketek, an FDA-approved antibiotic
which has since been linked to liver disorders and the FDA has been without a confirmed commissioner
deaths. for all but 18 months. Dr. von Eschenbach, an
The confirmation provides stability for the FDA as the oncologist and surgeon, previously served as director
Democrat-controlled Congress is expected to issue of the National Cancer Institute and as a chief academic
new regulations for the FDA. Pending legislation officer to the M. D. Anderson Cancer Center.
on drug safety, generic medicine issues, and funding
for FDA drug and device centers could substantially Bridget Behling, Meryl Eschen Mills, Jessica Smith,
affect the agency's regular operations. and Rebecca Wolf contributed to this column.
In the last decade, no FDA commissioner has held the
position for longer than two years. Ofthe last five years,
